Matrix Capital Management Company, LP 13D and 13G filings for Adaptimmune Therapeutics plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-08 10:30 am Sale | 2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP | Matrix Capital Management Company, LP | 0 0.000% | -135,000,000 (Position Closed) | Filing |
| 2024-12-05 5:17 pm Sale | 2024-11-30 | 13G | Adaptimmune Therapeutics plc ADAP | Matrix Capital Management Company, LP | 135,000,000 8.800% | -91,089,090 (-40.29%) | Filing |
| 2024-11-13 09:04 am Sale | 2024-09-30 | 13G | Adaptimmune Therapeutics plc ADAP | Matrix Capital Management Company, LP | 226,089,090 14.730% | -7,756,020 (-3.32%) | Filing |
| 2023-07-10 4:15 pm Unchanged | 2023-06-30 | 13G | Adaptimmune Therapeutics plc ADAP | Matrix Capital Management Company, LP | 233,845,110 17.290% | 0 (Unchanged) | Filing |
| 2021-02-16 10:03 am Purchase | 2020-12-31 | 13G | Adaptimmune Therapeutics plc ADAP | Matrix Capital Management Company, LP | 233,845,110 25.180% | 65,845,110 (+39.19%) | Filing |